Get the Stockscreener App
157.19
0.78%
1.185
Biogen Inc stock is traded at $157.19, with a volume of 294.42K.
It is up +0.78% in the last 24 hours and down -14.86% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$156.00
Open:
$157.17
24h Volume:
294.42K
Relative Volume:
0.25
Market Cap:
$22.53B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
8.5566
EPS:
18.37
Net Cash Flow:
$1.77B
1W Performance:
-4.66%
1M Performance:
-14.86%
6M Performance:
-30.95%
1Y Performance:
-31.52%
1-Day Range:
$154.74
$157.20
1-Week Range:
$153.62
$166.34
52-Week Range:
$153.62
$268.30
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BIIB | 157.13 | 22.53B | 9.61B | 1.62B | 1.77B | 18.37 |
| LLY | 742.95 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.13 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.43 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 170.45 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 98.29 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen (NASDAQ:BIIB) Given New $207.00 Price Target at Mizuho - MarketBeat
Primecap Management Co. CA Sells 23,215 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Unusual Options Activity For November 20 - Benzinga
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Yahoo Finance
ANCA Vasculitis Pipeline Trends 2024: Clinical Trials, - openPR
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
(BIIB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
European committee takes a second look at Alzheimer's drug and now says it should be approved - MSN
Biogen at the 7th Annual Evercore HealthCONx Conference - Biogen | Investor Relations
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen to Participate in the 7th Annual Evercore HealthCONx Conference - Biogen | Investor Relations
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - MSN
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III - BioSpace
Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation - PMLiVE
Thrivent Financial for Lutherans Reduces Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UCB: positive phase 3 results in lupus - Marketscreener.com
Empowered Funds LLC Has $3.67 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen: positive phase 3 results in lupus - Marketscreener.com
BIIBBiogen Inc. Latest Stock News & Market Updates - StockTitan
Biogen/UCB’s Lupus Drug Shows Consistent Efficacy Across Endpoints, Over Time - Citeline News & Insights
Dapirolizumab Pegol Phase 3 Data Presented at the American - GlobeNewswire
Biogen's Lupus Drug Shows 49.5% Response Rate in Phase 3 Trial, Beats Standard Care | BIIB Stock News - StockTitan
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Yahoo Finance
Needham downgrades Biogen on slow growth of Alzheimer's drug By Investing.com - Investing.com Canada
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales (NASDAQ:BIIB) - Seeking Alpha
Needham downgrades Biogen on slow growth of Alzheimer's drug - Investing.com
Opuviz is latest EC-approved ophthalmology biosimilar - The Pharma Letter
Biogen (NASDAQ:BIIB) Sets New 12-Month LowShould You Sell? - MarketBeat
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ - Biogen | Investor Relations
Biogen (NASDAQ:BIIB) Downgraded to "Hold" Rating by Needham & Company LLC - MarketBeat
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewswire
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewswire Inc.
Analyst recommendations: Biogen, HP, Moderna, Shell... - Marketscreener.com
KBC Group NV Has $6.44 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? - Insider Monkey
Top 10 Alzheimer’s Disease Therapeutics Companies | Provides Best TreatmentsMarket.us Media - Market.us Media - United States Market News
Seizert Capital Partners LLC Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mizuho Securities USA LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
ING Groep NV Has $3.81 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Impax Asset Management Group plc Has $7.52 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Los Angeles Capital Management LLC Purchases Shares of 4,282 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
How a Biogen drug set the stage for a new biotech targeting ALS - BioPharma Dive
BIIB (Biogen) Total Inventories : $2,469 Mil (As of Sep. 2024) - GuruFocus.com
Biogen Unusual Options Activity - Benzinga
Cornercap Investment Counsel Inc. Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe - Yahoo Finance
Biogen (NASDAQ:BIIB) Now Covered by Analysts at Wolfe Research - MarketBeat
Citigroup Upgrades Biogen (NASDAQ:BIIB) to Hold - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):